ScinoPharm, a leading active pharmaceutical ingredient (API) developer and manufacturer headquartered in Taiwan, today announced an investment into Tanvex Biologics, Inc., a United States company registered in the State of Delaware.

ScinoPharm, an active pharmaceutical ingredient (API) specialist, today announced audited record results for its fiscal year 2009. The company posted NT$3.791 billion in revenue, an increase of 20.54% over 2008.

ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), has commenced construction of a new plant on a 66670 square meter site.

ScinoPharm Taiwan, a leading active pharmaceutical ingredient (API) supplier to the global pharmaceutical and biotechnology industry, announced it has successfully passed a GMP inspection by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

"Our business strategy, which is focused on building a strong portfolio of oncology products and a growing base of global customers, continues to drive record performance." said Dr. Jo Shen, President and CEO of ScinoPharm.